Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator‐activated receptors (PPARs) in vivo
Open Access
- 1 July 2007
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (6) , 844-850
Abstract
Background and purpose: Recently, there has been much attention paid to understanding the molecular mechanisms underlying apoptosis and the functional consequences of apoptotic body clearance by phagocytes. In an attempt to investigate this latter aspect, the present study evaluated the anti‐inflammatory effects of in vivo administration of phosphatidylserine (PS) liposomes, a well‐characterised membrane component expressed during apoptosis. The participation of peroxisome proliferator‐activated receptors (PPARs) in PS‐mediated effects was also investigated.Experimental approach: The anti‐inflammatory effect of PS liposomes on the delayed phase of carrageenan mouse paw oedema was studied. PS liposomes were injected at different doses and times, after carrageenan. Hind paws were collected for evaluation of interleukin‐1β (IL‐1β) levels, myeloperoxidase (MPO) and N‐acetyl‐glucosaminidase (NAG) activities and Evans blue dye leakage. Participation of PPAR pathways was explored by using PPAR antagonists (BADGE and GW9662).Key results: Administration of PS, but not phosphatidylcholine (PC), liposomes (20–200 mg kg−1, i.p., 8 h after carrageenan) reduced the paw oedema in a dose‐dependent manner. PS liposomes were effective even when administered 24 and 48 h after carrageenan, a time at which indomethacin (1 mg kg−1, i.p.) had no significant effects. Carrageenan‐induced Evans blue leakage and IL‐1β production was decreased in PS‐treated paws. The PPAR antagonists (BADGE and GW9662) partially prevented the anti‐inflammatory effects of PS administration.Conclusions and implications: PS liposomes have anti‐inflammatory effects in vivo that are at least partly dependent on PPAR activation. Therapeutic strategies mimicking apoptosis may be useful for the treatment of inflammatory disorders.British Journal of Pharmacology (2007) 151, 844–850; doi:10.1038/sj.bjp.0707302Keywords
This publication has 37 references indexed in Scilit:
- Resolution of in flammation: state of the art, definitions and termsThe FASEB Journal, 2007
- Apoptotic cell removal in development and tissue homeostasisTrends in Immunology, 2006
- Resolution of inflammation: the beginning programs the endNature Immunology, 2005
- Peroxisome Proliferator-activated Receptor-γ as a Regulator of Lung Inflammation and RepairProceedings of the American Thoracic Society, 2005
- PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-?? IS A NEW THERAPEUTIC TARGET IN SEPSIS AND INFLAMMATIONShock, 2005
- Role of Peroxisome Proliferator-Activated Receptor g and Its Ligands in the Control of Immune ResponsesCritical Reviews in Immunology, 2003
- THE MODULATORY ROLE PLAYED BY TNF-α AND IL-1β IN THE INFLAMMATORY RESPONSES INDUCED BY CARRAGEENAN IN THE MOUSE MODEL OF PLEURISYCytokine, 2001
- Loss of Phospholipid Asymmetry and Surface Exposure of Phosphatidylserine Is Required for Phagocytosis of Apoptotic Cells by Macrophages and FibroblastsJournal of Biological Chemistry, 2001
- Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.Journal of Clinical Investigation, 1998
- Modalities for reducing interleukin 1 activity in diseaseImmunology Today, 1993